（来源：湖州日报） 转自：湖州日报 信中提及的，是一名因重症肺炎导致心、肺、肾等多脏器衰竭的年轻患者。当时，患者已陷入深度昏 迷、"白肺"、呼吸机下氧合不能维持、休克，生命体征极度不稳。谢波团队果断决策，启用代表顶尖生 命支持技术的ECMO（体外膜肺氧合）与CRRT（连续性肾脏替代治疗）等联合救治，支撑和维护患者 衰竭的心肺与肾脏及内环境功能，为受损脏器赢得了宝贵的自我修复机会和时间。 记者 张 璐 "在这与生命赛跑的20多个日日夜夜里，你们全力以赴、不辞劳苦、夜以继日；在我儿子生命垂危之 际，你们不放弃、不抛弃……生命的使者，你们最美。"这封手写的感谢信，被市急危重症医学中心 （重症方向）执行主任、湖州市中心医院重症医学科学科带头人谢波珍藏着。 "当多脏器衰竭这类最棘手的危重症来临时，我们能迅速打破专科壁垒，变分力为合力，启动'心—肺— 肾—肝'全方位的集束化支持。"谢波介绍，对于暴发性心肌炎、重症急性心肌梗死、重症肺炎、脓毒症 休克等危重症，中心已常规化开展ECMO、IABP（主动脉内球囊反搏）、多种模式CRRT以及重症超声 等技术的组合应用，形成了一套成熟的"重症救治技术包"。 在谢波看来，拥有ECMO ...

Core Insights - The Chinese medical device industry has undergone significant transformation since the country joined the WTO in 2001, leading to the establishment of a comprehensive network of sales, service, and training by multinational manufacturers [1][2] - The domestic production of medical devices has increased dramatically, with the localization rate of monitoring devices exceeding 85%, and the market share of Chinese medical devices in the global market is on the rise [2][3] - China's medical device sector is projected to grow, with over 35,000 production companies expected by the end of 2025 and a market size estimated to reach 1.22 trillion yuan [2] Industry Development - The medical device sector is a crucial pillar of healthcare, alongside medical services and pharmaceuticals, encompassing a wide range of products including diagnostic equipment and implants [1] - The emergence of numerous startups focused on independent research and development of medical devices has been driven by market demand [1] - The Chinese manufacturing industry has developed capabilities across nearly all categories of medical devices, with significant advancements in innovative products such as ECMO [3] Technological Advancements - The integration of advanced technologies such as artificial intelligence and 5G is expected to drive the next wave of innovation in medical devices, enabling new diagnostic and treatment methods [4] - The establishment of research and development centers by foreign companies in China highlights the strategic importance of the local market and supply chain [3] Market Dynamics - China's large population and diverse health needs are accelerating the pace of technological iteration in the global medical device industry [2] - The shift from "following" to "competing" and even "leading" in certain areas reflects the industry's evolution and the rise of "China Intelligent Manufacturing" [3]

Core Viewpoint - The article highlights the successful development and approval of a domestically produced ECMO (Extracorporeal Membrane Oxygenation) device by Shandong Hengxin Medical Equipment Co., showcasing the company's commitment to innovation and the support from regulatory authorities in China [2][4]. Company Overview - Shandong Hengxin Medical Equipment Co. is led by Liu Shuqin, a retired professor and expert in magnetic levitation, who aims to accelerate the development of portable and intelligent ECMO devices to fill domestic market gaps [2][3]. - The company has successfully obtained the third-class medical device registration certificate for its ECMO, marking it as the sixth approved ECMO product in China and the first in Shandong [2][3]. Research and Development - The R&D team at Hengxin Medical comprises experts from various fields, including mechanical, electrical, magnetic, control, and materials engineering, as well as medical professionals from critical care and emergency medicine [3]. - The ECMO device's blood flow control precision is achieved at 20 ml/min, with a temperature difference of 0.1 degrees Celsius, surpassing the regulatory requirements and reaching international standards [3]. Regulatory Support - The Shandong Provincial Drug Administration has provided significant support to Hengxin Medical, guiding the company through product testing, clinical trials, and quality management system establishment [4]. - The recent inclusion of ECMO in the National Medical Products Administration's priority approval list for high-end medical devices is seen as a major advantage for Hengxin Medical [4].

Core Insights - The article highlights a successful heart transplant surgery on a 6-month-old baby suffering from severe dilated cardiomyopathy, marking a significant achievement in pediatric cardiac care in East China [1][2][4] Group 1: Medical Procedure and Challenges - The baby, referred to as Duoduo, was placed on ECMO (extracorporeal membrane oxygenation) for 41 days to support her failing heart while waiting for a donor [2][3] - The pediatric heart transplant surgery is recognized as a high-difficulty procedure, especially in infants due to their small heart size and delicate blood vessels [4] - The surgical team, led by experts from Fudan University, successfully performed the transplant, ensuring the new heart was properly integrated into Duoduo's body [4] Group 2: Medical Team and Technology - The pediatric cardiac surgery team at Fudan University has developed a comprehensive treatment system for end-stage heart failure, including heart transplants and ECMO technology [5] - A multidisciplinary team approach, involving cardiac surgery, anesthesia, and intensive care, significantly enhances patient survival rates and quality of life [5] - The successful treatment of Duoduo demonstrates the hospital's technical capabilities in treating severe pediatric cardiovascular diseases and offers hope to other families facing similar challenges [5]

Core Insights - The Guangdong Province has released the "14th Five-Year Plan" emphasizing the strengthening of the medical device industry and promoting biomanufacturing and brain-machine interfaces as new economic growth points [1] - During the "14th Five-Year" period, China's medical equipment industry achieved a compound annual growth rate of approximately 10.7%, transitioning from a "follower" to a "runner" in high-end medical devices, with some areas achieving "leading" breakthroughs [1] Group 1: National Innovation Center - The National High-Performance Medical Device Innovation Center, established in April 2020, plays a crucial role in promoting high-quality innovation in China's medical device industry and is the only national-level manufacturing innovation center in this field [1][3] - The center has formed a collaborative entity consisting of leading enterprises, universities, and research institutions, achieving significant technological breakthroughs and fostering a number of innovative medical device companies [1][4] Group 2: Innovation and Support - The number of approved domestic innovative medical devices surged by 144% during the "14th Five-Year" period compared to the total from 2014 to 2020, supported by national policies [3] - The center has undertaken over 120 national and local research tasks, applied for 296 patents (with two-thirds being invention patents), and participated in the revision of 11 industry standards [3] Group 3: Collaborative Model - The center employs a model where enterprises participate in strategic planning, leading to collaborative results in technology innovation and application [5][6] - This model integrates resources from various sectors, ensuring that scientific innovation is aligned with commercial interests, thus enhancing the efficiency of technology transfer [6][7] Group 4: Future Outlook - The center aims to lead innovations in intelligent medical devices, particularly in artificial intelligence and brain-machine interfaces, which are expected to revolutionize the medical industry [8] - Current projects include the development of auditory and visual implantable brain-machine interface devices, as well as key technologies for brain function information translation and non-invasive brain information reading [8]

Core Viewpoint - The article highlights the urgent need to improve the non-emergency medical transport service system in China, especially in light of increasing diverse and personalized medical needs [1][4]. Summary by Sections Incident Overview - A father in Jiangxi complained about a charge of 28,000 yuan for an 800-kilometer transfer of his critically ill child, leading to an investigation by the Jiangxi Health Commission [2]. - The child was in a critical condition and required urgent transfer, which was facilitated by a private hospital's ambulance due to the lack of suitable vehicles from the original hospital [2][3]. Public Reaction - The incident sparked significant public debate, with some arguing that the fee was exorbitant and questioning potential kickback practices, while others defended the cost given the emergency nature of the transfer and the use of advanced medical equipment like ECMO [2][3]. - The Health Commission's response was criticized for not providing clear details on what constituted unreasonable charges and the basis for reasonable pricing [3]. Systemic Issues - The article points out that public ambulances in China rarely handle inter-provincial transfers due to regulatory and resource allocation issues, with emergency services primarily focused on local needs [3][4]. - The current system's limitations were highlighted, as the urgent nature of the child's condition did not fit neatly into existing categories of emergency and non-emergency transport [4]. Regulatory Recommendations - There is a call for the government to enhance regulation and oversight of the medical transport sector to eliminate gray areas, as evidenced by the family's payment directly to the driver's personal account without any receipts [4]. - The article emphasizes the need for a standardized non-emergency transport service system, with clear responsibilities, processes, and transparent pricing to address the growing demand for such services [4].

Core Viewpoint - The incident involving the high charge of 28,000 yuan for an 800-kilometer ambulance transfer has sparked significant public debate regarding the reasonableness of such fees and the regulatory framework surrounding medical transport services [1][2]. Group 1: Incident Overview - A father in Jiangxi complained about the 28,000 yuan charge for transferring his critically ill child over 800 kilometers, leading to an investigation by the Jiangxi Health Commission [1]. - The child was in urgent need of transfer due to a severe condition, and the ambulance service was provided by Nanchang Gan Medical Hospital, which was found to have unreasonable charges [1][3]. Group 2: Public Reaction and Concerns - Public opinion is divided; some view the fee as exorbitant and suspect potential kickbacks, while others argue that the service provided was akin to a mobile ICU, justifying the cost [2]. - The Jiangxi Health Commission's announcement did not clarify the specific issues with the charges or provide a reasonable fee standard, leaving many questions unanswered [2]. Group 3: Systemic Issues in Medical Transport - The lack of ambulances meeting cross-province transfer conditions at the treating hospital raises concerns about the medical transport system's shortcomings [3]. - The current system in China separates emergency and non-emergency transport, with public ambulances primarily serving local needs, which limits their availability for long-distance transfers [3][4]. Group 4: Regulatory and Market Considerations - The incident highlights the need for improved regulation and oversight in the non-emergency transport sector, especially as demand for such services grows [4]. - The introduction of market forces in areas where public resources are insufficient is necessary, but the government must enhance regulation to eliminate gray areas in service provision [4].